Alaunos Therapeutics, Inc.(TCRT)
Biotechnology
Cell Therapy (CAR-T, etc.)
| Filing Date | Insider | Type | 10b5-1 | Net Shares | Ownership change | Avg. Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| 2025-06-26 | Vieser Jaime Director | Purchase | +55,679.29 | +100.00%55,679.29 | $0.02 | $1,123 | View SEC filing | |
| 2025-06-26 | Postma Robert W Director | Purchase | +314,789.29 | +100.00%314,789.29 | $0.01 | $4,074 | View SEC filing | |
| 2025-04-15 | Postma Robert W Director | Purchase | +181,159 | +100.00%181,159 | $0.01 | $1,380 | View SEC filing | |
| 2025-01-03 | Vieser Jaime Director | Sale | -3,000 | -10.38%25,894 | $2.01 | $6,022 | View SEC filing | |
| 2023-09-05 | Boyle Kevin S. Sr. Chief Executive Officer | Sale | -68,014 | -7.85%798,236 | $0.14 | $9,542 | View SEC filing | |
| 2022-12-01 | Postma Robert W Director | Purchase | +750,000 | +17.65%5,000,000 | $0.65 | $487,500 | View SEC filing | |
| 2022-12-01 | Vieser Jaime Director | Purchase | +1,250,000 | +100.00%1,250,000 | $0.65 | $812,500 | View SEC filing | |
| 2021-12-27 | De Groot Eleanor EVP, Operations | Sale | -20,132 | -7.83%237,106 | $1.27 | $25,568 | View SEC filing | |
| 2021-11-17 | Boyle Kevin S. Sr. Chief Executive Officer | Purchase | +10,000 | +1.14%885,000 | $1.40 | $14,000 | View SEC filing | |
| 2021-10-04 | Vieser Jaime Director | Purchase | +100,000 | +16.52%705,321 | $1.91 | $191,000 | View SEC filing | |
| 2021-09-03 | Hagen Heidi Director | Purchase | +23,770 | +19.46%145,889 | $1.76 | $41,835 | View SEC filing | |
| 2021-09-03 | Weis Holger Director | Purchase | +50,000 | +71.26%120,167 | $1.83 | $91,500 | View SEC filing | |
| 2021-09-03 | Postma Robert W Director | Purchase | +75,000 | +1.39%5,451,870 | $1.73 | $129,750 | View SEC filing | |
| 2021-09-03 | Huang James Director | Purchase | +100,000 | +1200.05%108,333 | $1.71 | $171,000 | View SEC filing | |
| 2021-01-12 | Buck Jill EVP, GM Gene Therapy | Sale | -27,894 | -12.27%199,516 | $3.12 | $87,029 | View SEC filing | |
| 2021-01-12 | Lafond Kevin G SVP, Treasurer & CAO | Sale | -18,020 | -21.98%63,965 | $3.09 | $55,682 | View SEC filing | |
| 2021-01-12 | Hadfield Robert General Counsel and Secretary | Sale | -26,500 | -16.58%133,319 | $3.12 | $82,680 | View SEC filing | |
| 2021-01-06 | De Groot Eleanor EVP, GM Cell Therapy | Sale | -21,620 | -9.48%206,413 | $2.72 | $58,806 | View SEC filing | |
| 2021-01-06 | Cooper Laurence James Neil President and CEO | Sale | -105,693 | -5.55%1,799,280 | $2.71 | $286,428 | View SEC filing | |
| 2020-01-03 | MAUNEY DAVID M MD President | Sale | -22,394 | -10.29%195,278 | $4.55 | $101,893 | View SEC filing | |
| 2020-01-03 | Lafond Kevin G SVP, Treasurer & CAO | Sale | -21,570 | -25.21%63,985 | $4.55 | $98,144 | View SEC filing | |
| 2020-01-03 | Hadfield Robert General Counsel and Secretary | Sale | -16,853 | -14.33%100,719 | $4.55 | $76,681 | View SEC filing | |
| 2020-01-03 | De Groot Eleanor EVP, GM Cell Therapy | Sale | -24,890 | -12.49%174,333 | $4.55 | $113,250 | View SEC filing | |
| 2020-01-03 | Buck Jill EVP, GM Gene Therapy | Sale | -27,923 | -13.85%173,710 | $4.55 | $127,050 | View SEC filing | |
| 2019-12-31 | Cooper Laurence James Neil Chief Executive Officer | Sale | -110,694 | -6.00%1,733,273 | $4.88 | $540,187 | View SEC filing |
1-25 of 52